MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.

$19.30  +0.25 (1.31%)
As of 02/24/2021 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA
USA
06/28/2017
68,497,425
858,626
$1,304,875,946
0.00%
SEC Edgar Online
10-Q
10-K
59045L106
US59045L1061
BF3NP05

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-17.30
5.15
0.00
-29.78%
-8,772.91%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy